Department of Surgery, University of Michigan Hospital, Ann Arbor, MI, United States.
Department of Infectious Diseases, Xiangya 2nd Hospital, Central South University, Changsha, China.
Front Immunol. 2021 Nov 4;12:761946. doi: 10.3389/fimmu.2021.761946. eCollection 2021.
Peptidylarginine deiminases (PADs) are a group of enzymes that catalyze post-translational modifications of proteins by converting arginine residues into citrullines. Among the five members of the PAD family, PAD2 and PAD4 are the most frequently studied because of their abundant expression in immune cells. An increasing number of studies have identified PAD2 as an essential factor in the pathogenesis of many diseases. The successes of preclinical research targeting PAD2 highlights the therapeutic potential of PAD2 inhibition, particularly in sepsis and autoimmune diseases. However, the underlying mechanisms by which PAD2 mediates host immunity remain largely unknown. In this review, we will discuss the role of PAD2 in different types of cell death signaling pathways and the related immune disorders contrasted with functions of PAD4, providing novel therapeutic strategies for PAD2-associated pathology.
肽基精氨酸脱亚氨酶(PADs)是一组通过将精氨酸残基转化为瓜氨酸来催化蛋白质翻译后修饰的酶。在 PAD 家族的五个成员中,由于其在免疫细胞中的大量表达,PAD2 和 PAD4 是研究最多的两种酶。越来越多的研究表明 PAD2 是许多疾病发病机制中的一个重要因素。针对 PAD2 的临床前研究的成功突出了 PAD2 抑制的治疗潜力,特别是在脓毒症和自身免疫性疾病中。然而,PAD2 介导宿主免疫的潜在机制在很大程度上仍然未知。在这篇综述中,我们将讨论 PAD2 在不同类型的细胞死亡信号通路中的作用以及与 PAD4 功能相对比的相关免疫紊乱,为 PAD2 相关病理学提供新的治疗策略。